Table 2. Geometric Mean Level Ratio at Month 7 and Month 12 vs Baseline for HPV-6, -11, -16, and -18a.
| Anti-HPV Type | GMR (95% CI)b | P Valuec | ||
|---|---|---|---|---|
| Posttransplant | Healthy Volunteers (n = 20) | |||
| Receiving Immunosuppression (n = 23) | Not Receiving Immunosuppression (n = 21) | |||
| At Month 7 Since Initial Vaccination (1 mo after dose 3) | ||||
| Anti-HPV-6 | 28.8 (8.1-102.1) | 106.6 (41.9-271.3) | 104.0 (66.1-163.8) | .17 |
| Anti-HPV-11 | 60.3 (15.9-228.5) | 172.0 (70.9-417.4) | 181.1 (121.4-270.1) | .51 |
| Anti-HPV-16 | 120.1 (32.8-439.9) | 409.8 (182.7-919.1) | 218.0 (114.4-415.3) | .26 |
| Anti-HPV-18 | 34.7 (11.4-105.7) | 108.7 (41.8-283.1) | 50.2 (29.6-85.1) | .13 |
| At Month 12 Since Initial Vaccination (6 mo after dose 3) | ||||
| Anti-HPV-6 | 9.3 (3.6-23.8) | 26.4 (12.0-58.1) | 31.0 (19.8-48.6) | .06 |
| Anti-HPV-11 | 20.6 (7.4-57.8) | 45.9 (21.7-97.1) | 46.9 (30.7-71.5) | .41 |
| Anti-HPV-16 | 39.4 (15.3-101.8) | 118.9 (62.5-226.3) | 58.3 (32.8-103.4) | .09 |
| Anti-HPV-18 | 11.5 (4.7-28.3) | 35.5 (15.4-81.6) | 12.1 (7.7-19.0) | .052 |
Abbreviations: GMR, geometric mean level ratio; HPV, human papillomavirus.
Levels lower than the cutoff were given the value of 4 EU/mL. GMR was defined as the ratio of the geometric mean levels (EU/mL) at month 7 or month 12 months vs baseline (prevaccination, day 1).
All GMRs were significantly greater than 1; P < .001.
P value using Kruskal-Wallis test to compare the 3 study groups. There were no significant differences in GMR among the study groups for anti-HPV-6, -11, -16, and -18 type at months 7 or 12 (all P > .05). Wilcoxon rank-sum tests were used to assess the pairwise differences between any 2 study groups using a significance level of .002 after Bonferroni correction and none of the pairwise comparisons showed significant difference (all P > .03, not included in Table 2).